Myomo Inc. — Cyborg Score 6/10

Solid
Medical Devices - Powered Exoskeletons & Rehabilitation Robotics

Strategic Profile

Myomo is positioned in the rehabilitation and assistive technology market, leveraging proprietary electromyography (EMG) technology and robotics. The company targets hospital rehabilitation centers, outpatient facilities, and home care settings, with potential for expansion into broader neurological recovery applications.

Cyborg Score Rationale

Myomo operates in a high-growth medical device segment with FDA clearance and expanding reimbursement coverage. However, the company faces typical biomedical small-cap risks including limited scale, competitive pressures from larger medical device companies, and market adoption challenges.

Top Insights

  • MyoPro is the only FDA-cleared wearable exoskeleton device for upper limb paralysis with expanding insurance coverage
  • Market opportunity for stroke and neurological injury rehabilitation is substantial and growing globally
  • Company has transitioned toward recurring revenue model through rental and leasing programs
  • Competition emerging from larger medical device manufacturers and international robotics companies

Named Competitors

  • Stroke Recovery Therapy — Conventional rehabilitation without powered assistance
  • Exoskeleton Platforms — Emerging powered exoskeleton competitors globally
  • Assistive Devices — Potential future entrants in powered orthotic space

Recent Developments

  • (2025) Expansion of insurance reimbursement coverage for MyoPro device
  • (2025) Increased adoption in hospital and rehabilitation center networks
  • (2024) Strategic partnerships to expand clinical distribution

Open the full interactive Myomo Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →